Micronuclei, a biomarker for chemoprevention trials

Results of a randomized study in oral pre-malignancy

S. E. Benner, S. M. Lippman, Michael J Wargovich, J. J. Lee, M. Velasco, J. W. Martin, B. B. Toth, W. K. Hong

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Biomarkers are being sought that could serve as surrogate end points for chemoprevention trials. Micronuclei, cytoplasmic fragments of DNA, have been proposed as a biomarker and studied in oral pre-malignancy. This study evaluated micronuclei frequency in a randomized chemoprevention trial of oral pre-malignancy. A recent clinical trial evaluated the responses of pre-malignant oral lesions to 3 months of therapy with isotretinoin followed by 9 months of either low-dose isotretinoin or beta-carotene. For 57 study participants, micronuctei were counted in mucosal scrapings of the lesion and in normalappearing mucosa at baseline and following 3 months and 12 months of therapy. Micronuclei counts were higher in scrapings from the lesion than in the normal-appearing mucosa. Following 3 months of isotretinoin, the micronuclei counts in scrapings of the lesion were significantly reduced. With treatment, the mean micronuclei count declined at 3 months. In a randomized comparison, both isotretinoin and beta-carotene maintained the suppression of micronuclei. The change in micronuclei count was not associated with the clinical or histological response to treatment. Chemoprevention treatment with isotretinoin led to a reduction in frequency of micronuclei, a marker of recent DNA injury, which was then maintained by both isotretinoin and beta-carotene.

Original languageEnglish (US)
Pages (from-to)457-459
Number of pages3
JournalInternational Journal of Cancer
Volume59
Issue number4
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Isotretinoin
Chemoprevention
Biomarkers
beta Carotene
Neoplasms
Mucous Membrane
Therapeutics
DNA Damage
Clinical Trials
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Micronuclei, a biomarker for chemoprevention trials : Results of a randomized study in oral pre-malignancy. / Benner, S. E.; Lippman, S. M.; Wargovich, Michael J; Lee, J. J.; Velasco, M.; Martin, J. W.; Toth, B. B.; Hong, W. K.

In: International Journal of Cancer, Vol. 59, No. 4, 1994, p. 457-459.

Research output: Contribution to journalArticle

Benner, S. E. ; Lippman, S. M. ; Wargovich, Michael J ; Lee, J. J. ; Velasco, M. ; Martin, J. W. ; Toth, B. B. ; Hong, W. K. / Micronuclei, a biomarker for chemoprevention trials : Results of a randomized study in oral pre-malignancy. In: International Journal of Cancer. 1994 ; Vol. 59, No. 4. pp. 457-459.
@article{7a6ac3f68b4a466e90f3edd3afdb5536,
title = "Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre-malignancy",
abstract = "Biomarkers are being sought that could serve as surrogate end points for chemoprevention trials. Micronuclei, cytoplasmic fragments of DNA, have been proposed as a biomarker and studied in oral pre-malignancy. This study evaluated micronuclei frequency in a randomized chemoprevention trial of oral pre-malignancy. A recent clinical trial evaluated the responses of pre-malignant oral lesions to 3 months of therapy with isotretinoin followed by 9 months of either low-dose isotretinoin or beta-carotene. For 57 study participants, micronuctei were counted in mucosal scrapings of the lesion and in normalappearing mucosa at baseline and following 3 months and 12 months of therapy. Micronuclei counts were higher in scrapings from the lesion than in the normal-appearing mucosa. Following 3 months of isotretinoin, the micronuclei counts in scrapings of the lesion were significantly reduced. With treatment, the mean micronuclei count declined at 3 months. In a randomized comparison, both isotretinoin and beta-carotene maintained the suppression of micronuclei. The change in micronuclei count was not associated with the clinical or histological response to treatment. Chemoprevention treatment with isotretinoin led to a reduction in frequency of micronuclei, a marker of recent DNA injury, which was then maintained by both isotretinoin and beta-carotene.",
author = "Benner, {S. E.} and Lippman, {S. M.} and Wargovich, {Michael J} and Lee, {J. J.} and M. Velasco and Martin, {J. W.} and Toth, {B. B.} and Hong, {W. K.}",
year = "1994",
doi = "10.1002/ijc.2910590403",
language = "English (US)",
volume = "59",
pages = "457--459",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Micronuclei, a biomarker for chemoprevention trials

T2 - Results of a randomized study in oral pre-malignancy

AU - Benner, S. E.

AU - Lippman, S. M.

AU - Wargovich, Michael J

AU - Lee, J. J.

AU - Velasco, M.

AU - Martin, J. W.

AU - Toth, B. B.

AU - Hong, W. K.

PY - 1994

Y1 - 1994

N2 - Biomarkers are being sought that could serve as surrogate end points for chemoprevention trials. Micronuclei, cytoplasmic fragments of DNA, have been proposed as a biomarker and studied in oral pre-malignancy. This study evaluated micronuclei frequency in a randomized chemoprevention trial of oral pre-malignancy. A recent clinical trial evaluated the responses of pre-malignant oral lesions to 3 months of therapy with isotretinoin followed by 9 months of either low-dose isotretinoin or beta-carotene. For 57 study participants, micronuctei were counted in mucosal scrapings of the lesion and in normalappearing mucosa at baseline and following 3 months and 12 months of therapy. Micronuclei counts were higher in scrapings from the lesion than in the normal-appearing mucosa. Following 3 months of isotretinoin, the micronuclei counts in scrapings of the lesion were significantly reduced. With treatment, the mean micronuclei count declined at 3 months. In a randomized comparison, both isotretinoin and beta-carotene maintained the suppression of micronuclei. The change in micronuclei count was not associated with the clinical or histological response to treatment. Chemoprevention treatment with isotretinoin led to a reduction in frequency of micronuclei, a marker of recent DNA injury, which was then maintained by both isotretinoin and beta-carotene.

AB - Biomarkers are being sought that could serve as surrogate end points for chemoprevention trials. Micronuclei, cytoplasmic fragments of DNA, have been proposed as a biomarker and studied in oral pre-malignancy. This study evaluated micronuclei frequency in a randomized chemoprevention trial of oral pre-malignancy. A recent clinical trial evaluated the responses of pre-malignant oral lesions to 3 months of therapy with isotretinoin followed by 9 months of either low-dose isotretinoin or beta-carotene. For 57 study participants, micronuctei were counted in mucosal scrapings of the lesion and in normalappearing mucosa at baseline and following 3 months and 12 months of therapy. Micronuclei counts were higher in scrapings from the lesion than in the normal-appearing mucosa. Following 3 months of isotretinoin, the micronuclei counts in scrapings of the lesion were significantly reduced. With treatment, the mean micronuclei count declined at 3 months. In a randomized comparison, both isotretinoin and beta-carotene maintained the suppression of micronuclei. The change in micronuclei count was not associated with the clinical or histological response to treatment. Chemoprevention treatment with isotretinoin led to a reduction in frequency of micronuclei, a marker of recent DNA injury, which was then maintained by both isotretinoin and beta-carotene.

UR - http://www.scopus.com/inward/record.url?scp=0028127247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028127247&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910590403

DO - 10.1002/ijc.2910590403

M3 - Article

VL - 59

SP - 457

EP - 459

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -